The Role of Early Diagnosis in Shaping the axSpA Treatment Market
The Role of Early Diagnosis in Shaping the axSpA Treatment Market
Blog Article
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that causes back pain and stiffness from inflammation of the spine and pelvis. This disease mostly affects young adults between the ages of 17 and 45 years. The two main types of axSpA are ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).
Key symptoms of Axial Spondyloarthritis (axSpA) Treatment Market include chronic lower back pain, fatigue, and morning stiffness lasting more than 30 minutes. Symptoms often improve with exercise but worsen with inactivity. Biologics such as tumor necrosis factor (TNF) inhibitors are effective in treating the signs and symptoms and inhibiting the progression of structural damage of axSpA.
The axial spondyloarthritis (axSpA) treatment market is estimated to be valued at USD 6.02 billion in 2024 and is expected to reach USD 10 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Key Takeaways
Key players operating in the Axial Spondyloarthritis (axSpA) market are Johnson & Johnson, AbbVie, UCB, Amgen, copyright, and Eli Lilly. UCB's Cimzia and AbbVie's Humira are the leading biologics for treating axSpA.
The rising prevalence of axSpA and growing patient awareness about the disease diagnosis and management is fueling the demand for axSpA treatment drugs. Early diagnosis and treatment interventions are important to avoid long-term consequences like ankylosis.
Development of novel targeted oral drugs with better safety profiles than biologics and pipeline drugs in late stages are expected to drive technological advancements in axSpA treatment over the forecast period. Oral JAK inhibitors like copyright's abrocitinib showed promise in phase 3 trials for treating active axSpA.
Market Trends
Growing preference for personalized treatment regimens: Given the heterogeneity of axSpA disease, personalized treatment approaches that consider individual disease characteristics, prognosis, and comorbidities are gaining prominence. This allows targeting the right therapy to the right patient.
Shift towards early treatment intervention: With growing understanding about disease progression, new treatment guidelines emphasize treating axSpA early and aggressively to achieve optimal outcomes. Early biologics or JAK inhibitors are being viewed favorably to prevent long term damage.
Market Opportunities
Untapped growth potential in emerging Asian and Latin American countries: Rising healthcare expenditures, large patient pools, and evolving reimbursement scenarios in developing nations provide potential opportunities for market expansion.
Lifecycle management of blockbuster biologics: Key players are exploring new indications, novel formulations, and combination therapies of their successful biologics going off patent to leverage existing market presence and brands. This ensures sustainable growth.
Impact of COVID-19 on Axial Spondyloarthritis (axSpA) Treatment Market Growth
The COVID-19 pandemic has significantly impacted the Axial Spondyloarthritis (axSpA) treatment market. During the initial phase of the pandemic, many routine appointments and elective surgeries were postponed to avoid unnecessary exposure and conserve healthcare resources for COVID-19 patients. This resulted in reduction in number of new patients being diagnosed with axSpA. Also, several ongoing clinical trials in this field were temporarily halted or delayed.
However, telehealth became an important tool for healthcare providers to continue the management of existing axSpA patients during this period. Video or phone consultations helped in remote monitoring of patients and making necessary adjustments in their treatment plans. The shift towards telemedicine is likely to have long lasting effects on how axSpA care is delivered even in the post pandemic era. With resumption of normal healthcare services, new patient diagnosis and enrollment in clinical trials has picked up pace now but it may take some time to reach pre-COVID levels.
Geographical Regions with Highest Market Value
North America has historically been the largest and most lucrative market for axSpA treatment globally. This is because of high disease prevalence, widespread health insurance coverage and presence of major pharmaceutical companies. The United States alone captures over 50% share of the total North American axSpA drugs market value owing to its huge patient population and higher per capita healthcare spending.
Fastest Growing Regional Market
Asia Pacific region is projected to witness the fastest growth during the forecast period. Factors such as rising incidence rates of axSpA especially in China and India due to improved diagnostics, rapidly developing healthcare infrastructure and increasing medical expenditures are contributing to this growth. In addition, growing geriatric population susceptible to develop axSpA and emergence of local biosimilar drugs at lower costs are creating new opportunities for market expansion in Asia Pacific.
Get more insights on: Axial Spondyloarthritis (axSpA) Treatment Market
Get this Report in Japanese Language: 軸性脊椎関節炎（axSpA）治療市場
Get this Report in Korean Language: 축성 척추관절염(axSpA) 치료 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)